KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Construction in Progress: 2013

  • Sarepta Therapeutics' Construction in Progress was N/A to $11.3 million in Q4 2013 from the same period last year, while for Dec 2013 it was $11.3 million, marking a year-over-year change of. This contributed to the annual value of $11.3 million for FY2013, which is N/A change from last year.
  • According to the latest figures from Q4 2013, Sarepta Therapeutics' Construction in Progress is $11.3 million.
  • In the past 5 years, Sarepta Therapeutics' Construction in Progress ranged from a high of $11.3 million in Q4 2013 and a low of $11.3 million during Q4 2013.
  • Moreover, its 1-year median value for Construction in Progress was $11.3 million (2013), whereas its average is $11.3 million.